XML 43 R49.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Selected Quarterly Financial Data (unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 29, 2019
Selected Quarterly Financial Information [Abstract] |
Summary of Selected Quarterly Financial Data (unaudited) | Selected unaudited quarterly financial data for the years 2019 and 2018 are summarized below:
|  | 2019 |  | 2018
(Dollars in Millions Except Per Share Data) |  | First Quarter (1) |  | Second Quarter (2) |  | Third Quarter (3) |  | Fourth Quarter (4) |  | First Quarter (5) |  | Second Quarter (6) |  | Third Quarter (7) |  | Fourth Quarter (8)
Segment sales to customers |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumer |  | $ | 3,318 |  |  | 3,544 |  |  | 3,469 |  |  | 3,567 |  |  | 3,398 |  |  | 3,504 |  |  | 3,415 |  |  | 3,536 |
Pharmaceutical |  | 10,244 |  |  | 10,529 |  |  | 10,877 |  |  | 10,548 |  |  | 9,844 |  |  | 10,354 |  |  | 10,346 |  |  | 10,190 |
Medical Devices |  | 6,459 |  |  | 6,489 |  |  | 6,383 |  |  | 6,632 |  |  | 6,767 |  |  | 6,972 |  |  | 6,587 |  |  | 6,668 |
Total sales |  | 20,021 |  |  | 20,562 |  |  | 20,729 |  |  | 20,747 |  |  | 20,009 |  |  | 20,830 |  |  | 20,348 |  |  | 20,394 |
Gross profit |  | 13,406 |  |  | 13,622 |  |  | 13,862 |  |  | 13,613 |  |  | 13,395 |  |  | 13,903 |  |  | 13,759 |  |  | 13,433 |
Earnings before provision for taxes on income |  | 4,422 |  |  | 7,041 |  |  | 1,647 |  |  | 4,218 |  |  | 5,481 |  |  | 4,973 |  |  | 4,423 |  |  | 3,122 |
Net earnings |  | 3,749 |  |  | 5,607 |  |  | 1,753 |  |  | 4,010 |  |  | 4,367 |  |  | 3,954 |  |  | 3,934 |  |  | 3,042 |
Basic net earnings per share |  | $ | 1.41 |  |  | 2.11 |  |  | 0.67 |  |  | 1.52 |  |  | 1.63 |  |  | 1.47 |  |  | 1.47 |  |  | 1.14 |
Diluted net earnings per share |  | $ | 1.39 |  |  | 2.08 |  |  | 0.66 |  |  | 1.50 |  |  | 1.60 |  |  | 1.45 |  |  | 1.44 |  |  | 1.12 |
(1) | The first quarter of 2019 includes a gain of $0.3 billion after-tax ($0.3 billion before-tax) related to the Company's previously held equity investment in DR. CI:LABO, an in-process research and development expense of $703 million after-tax ($890 million before-tax) related to the Alios asset, a litigation expense of $342 million after-tax ($423 million before-tax), an unrealized gain on securities of $125 million after-tax ($158 million before-tax), a restructuring related charge of $75 million after-tax ($90 million before-tax), and acquisition related costs of $60 million after-tax ($67 million before-tax).
(2) | The second quarter of 2019 includes a gain of $1.5 billion after-tax ($2.0 billion before-tax) from the divestiture of the ASP business, a litigation expense of $342 million after-tax ($409 million before-tax), an unrealized gain on securities of $117 million after-tax ($148 million before-tax), a restructuring related charge of $116 million after-tax ($142 million before-tax) and acquisition related costs of $50 million after-tax ($55 million before-tax).
(3) | The third quarter of 2019 includes a litigation expense of $3,080 million after-tax ($4,000 million before-tax) related to the agreement in principle to settle opioid litigation, a restructuring related charge of $106 million after-tax ($128 million before-tax), acquisition related costs of $88 million after-tax ($107 million before-tax), a $391 million benefit after-tax from the impact of tax legislation, and an unrealized loss on securities of $71 million after-tax ($89 million before-tax).
(4) | The fourth quarter of 2019 includes a litigation expense of $251 million after-tax ($264 million before-tax), an unrealized gain on securities of $277 million after-tax ($350 million before-tax), a restructuring related charge of $214 million after-tax ($251 million before-tax), a $184 million benefit after-tax from the impact of tax legislation, and acquisition related costs of $82 million after-tax ($90 million before-tax).
(5) | The first quarter of 2018 includes an Actelion acquisition related cost of $92 million after-tax ($96 million before-tax) and a restructuring related charge of $81 million after-tax ($107 million before-tax).
(6) | The second quarter of 2018 includes a litigation expense of $609 million after-tax ($703 million before-tax) and a restructuring related charge of $152 million after-tax ($176 million before-tax).
(7) | The third quarter of 2018 includes an in-process research and development expense of $859 million after-tax ($1,126 million before-tax) related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $184 million after and before tax, a restructuring related charge of $162 million after-tax ($190 million before-tax) and a $265 million benefit after-tax from the impact of tax legislation.
(8) The fourth quarter of 2018 includes a litigation expense of $1,113 million after-tax ($1,288 million before-tax), a restructuring related charge of $190 million after-tax ($227 million before-tax) and a $137 million benefit after-tax from the impact of tax legislation.

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SelectedQuarterlyFinancialInformationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration